EMERGENT BIOSOLUTIONS INC. Payments of Debt Issuance Costs
EMERGENT BIOSOLUTIONS INC. (EBS) reported Payments of Debt Issuance Costs of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-02-27
- EMERGENT BIOSOLUTIONS INC. payments of debt issuance costs for the quarter ending 2025-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments of debt issuance costs for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. payments of debt issuance costs for the quarter ending 2024-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments of debt issuance costs for the quarter ending 2024-09-30 was $8.70M.
- EMERGENT BIOSOLUTIONS INC. payments of debt issuance costs for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. payments of debt issuance costs for fiscal 2024 was $14.60M.
- EMERGENT BIOSOLUTIONS INC. payments of debt issuance costs for fiscal 2023 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments of debt issuance costs for fiscal 2022 was $0.00.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month | Payments of Debt Issuance Costs 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $8.70M derived: sum of 2 quarters · filed 2026-02-27 | $14.60M 10-K · filed 2026-02-27 | ||
| 2024-09-30 | $8.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $14.60M 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | $5.90M 10-Q · filed 2025-08-07 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 derived: sum of 2 quarters · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-07 | ||||
| 2022-12-31 | $0.00 10-K · filed 2025-03-04 | ||||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $0.00 10-K/A · filed 2023-12-11 | |||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-05 | ||||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $8.40M 10-K/A · filed 2023-12-11 | |||
| 2020-09-30 | $8.40M 10-Q · filed 2021-11-05 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $0.00 10-K · filed 2022-02-25 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-06 | ||||
| 2018-12-31 | $13.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $13.40M 10-K · filed 2021-02-19 | |||
| 2018-09-30 | $0.00 10-Q · filed 2018-11-02 | ||||
| 2017-12-31 | -$26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $1.40M 10-K · filed 2020-02-25 | $1.43M 10-K · filed 2018-02-23 | ||
| 2017-09-30 | $1.43M 10-Q · filed 2018-11-02 | ||||
| 2016-12-31 | $0.00 10-K · filed 2019-02-22 | ||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |